The diagnosis and monitoring of transitional cell cancer of the urinary tract through nuclear matrix protein 22.
- Author:
Hui-Qing CHEN
1
;
Cun-Zhi HAN
;
Li-Li DU
;
Yu CUI
;
Dong-Zhi PANG
;
Jie-Xian JING
;
Xian-Wen ZHAO
;
Bao-Guo TIAN
;
Zhen-Guo MI
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; urine; Carcinoma, Transitional Cell; diagnosis; urine; Child; Female; Humans; Male; Middle Aged; Nuclear Proteins; urine; Urinary Bladder Neoplasms; diagnosis; urine
- From: Chinese Journal of Preventive Medicine 2007;41 Suppl():84-86
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the urinary nuclear matrix protein (NMP22) as an adjuvant diagnostic index for transitional cell carcinoma of urinary tract and monitoring the state of disease.
METHODSUrinary samples were collected from 262 patients with transitional cell carcinoma, 198 non-transitional cell carcinoma of the urinary tract and 65 patients with benign diseases. Urinary NMP22 concentration was determined through enzyme linked immunosorbent assay (ELISA).
RESULTSThe urinary NMP22 concentration had significant difference among the three groups (Kruskal Wallis, chi(2) = 197.17 P < 0.001). The detection sensitivity and specificity of urinary NMP22 to transitional cell carcinoma were 71.37% and 87.69% respectively. The NMP22 concentration showed significant difference among three groups divided according to the pathological grade (Kruskal-Wallis test, chi(2) = 34.06 P < 0.01). The NMP22 concentration was significant lower in the recovery patients after the operation than the peoples of pre-operation and recurrence (Kruskal-Wallis test, chi(2) = 37.53, P < 0.001).
CONCLUSIONMP22 is a helpful tumor marker for the diagnosis of transitional cell carcinoma and monitoring the state of illness with increased efficacy.
